PI-55,98.98%
产品编号:Bellancom-141519| CAS NO:1122579-42-3| 分子式:C13H13N5O| 分子量:255.28
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
PI-55
产品介绍 | PI-55 是特异性 cytokinin receptor 抑制剂。PI-55 在结构上与 6-benzylaminopurine (BAP) 相关,并被证明能竞争性地抑制 BAP 与拟南芥特异性受体 CRE1/AHK4 和 AHK3 的结合。PI-55 抑制细胞分裂素诱导吸器形成和寄生虫侵袭性增加。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | PI-55 is a specific cytokinin receptor inhibitor. PI-55 is structurally related to 6-benzylaminopurine (BAP) and was shown to inhibit competitively BAP binding on Arabidopsis-specific receptors CRE1/AHK4 and AHK3. PI-55 inhibits cytokinins induced haustorium formation and increased parasite aggressiveness. | ||||||||||||||||
体外研究 |
PI-55 at high concentrations (10 μM and 100 μM), which causes an incomplete blocking of early haustorial structure development, especially when cytokinin activity promotes it. PI-55 treatment also reduces the overall aggressiveness of P. ramosa when applied with BAP in comparison with BAP alone, suggesting that the signaling pathway leading to early haustorial structure formation involves histidine kinase receptors homologous to CRE1/AHK4 and AHK3. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 | |||||||||||||||||
体内研究 | |||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 12.5 mg/mL (48.97 mM; ultrasonic and warming and heat to 70°C) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
参考文献 |